Synthetic Genes was the largest of Twist Bioscience Corp’s 3 reported lines in fiscal 2025, at $113.60M — 78% of $145.02M.
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Synthetic Genes | $61.51M | $73.54M | $92.68M | $113.60M | |||||
| Ngs Tools | $99.31M | $123.71M | — | — | |||||
| Antibody Discovery | $24.17M | $23.17M | $20.33M | — | |||||
| Oligo Pools | $12.42M | $14.49M | $16.91M | $20.23M | |||||
| Dna Libraries | $6.15M | — | $13.93M | $11.18M | |||||
| Dna & Biopharma Libraries | — | — | — | — | |||||
| Total | $203.57M | $234.91M | $143.85M | $145.02M |
In fiscal 2025, which ended September 30, 2025, the 3 revenue lines Twist Bioscience Corp reported in this breakdown added up to $145.02M. That is less than the $161.48M in its breakdown by revenue line, so these revenue lines do not account for all of its revenue that year. Synthetic Genes was the largest revenue line, at $113.60M or 78.3% of the total, followed by Oligo Pools ($20.23M, 14.0%) and Dna Libraries ($11.18M, 7.7%). Together, the two largest revenue lines made up 92.3% of this total.
Compared with fiscal 2024, Synthetic Genes grew the fastest, rising 22.6% to $113.60M. Dna Libraries fell the most, down 19.7% to $11.18M. Because revenue lines were added or dropped between the two years, part of this reflects how Twist Bioscience Corp regrouped its reporting.
The table also keeps 3 revenue lines that Twist Bioscience Corp no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2025, as reported in Twist Bioscience Corp's annual filings.
Industrial Chemicals/Materials was the largest of Twist Bioscience Corp’s 3 reported lines in fiscal 2025, at $93.25M — 58% of $161.48M.
| Information by industry sector. | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Healthcare | $106.36M | $137.15M | $168.96M | — | |||
| Industrial Chemicals/Materials | $57.94M | — | — | $93.25M | |||
| Academic Research | $37.10M | $45.85M | $58.45M | $65.86M | |||
| Food/Agriculture | $2.17M | $2.79M | $2.09M | $2.37M | |||
| Total | $203.57M | $185.79M | $229.50M | $161.48M |
In fiscal 2025, which ended September 30, 2025, the 3 revenue lines Twist Bioscience Corp reported in this breakdown added up to $161.48M. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $229.50M reported that year. Industrial Chemicals/Materials was the largest revenue line, at $93.25M or 57.7% of the total, followed by Academic Research ($65.86M, 40.8%) and Food/Agriculture ($2.37M, 1.5%). Together, the two largest revenue lines made up 98.5% of this total.
The table also keeps 1 revenue line that Twist Bioscience Corp no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2019 to 2025, as reported in Twist Bioscience Corp's annual filings.
Americas was the largest of Twist Bioscience Corp’s 3 reported lines in fiscal 2022, at $122.47M — 60% of $203.57M.
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|
| Americas | $36.93M | $59.16M | $77.91M | $122.47M | ||
| Emea | $14.69M | $25.82M | $44.12M | $62.08M | ||
| United States | — | — | — | — | ||
| Apac | $2.76M | $5.12M | $10.30M | $19.01M | ||
| Asia Pacific | — | — | — | — | ||
| North America | — | — | — | — | ||
| Total | $54.39M | $90.10M | $132.33M | $203.57M |
In fiscal 2022, which ended September 30, 2022, the 3 regions Twist Bioscience Corp reported in this breakdown added up to $203.57M. That was up 53.8% from $132.33M in fiscal 2021. Americas was the largest region, at $122.47M or 60.2% of the total, followed by Emea ($62.08M, 30.5%) and Apac ($19.01M, 9.3%). Together, the two largest regions made up 90.7% of this total.
Compared with fiscal 2021, Apac grew the fastest, rising 84.6% to $19.01M. Every sizeable region reported in both years grew. Over fiscal 2019 to 2022, revenue across these regions went from $54.39M to $203.57M, a compound annual growth rate of 55.3%. Americas' share of the total fell from 67.9% to 60.2% over the same years.
The table also keeps 3 regions that Twist Bioscience Corp no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2022, as reported in Twist Bioscience Corp's annual filings.
Twist Bioscience Corp (TWST) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Synthetic Genes, with $113.60M or 78.3% of the total, followed by Oligo Pools at $20.23M (14.0%).
Synthetic Genes was Twist Bioscience Corp's largest revenue line in fiscal 2025, with $113.60M in revenue, 78.3% of the $145.02M reported across its 3 revenue lines.
Americas was Twist Bioscience Corp's largest region in fiscal 2022, with $122.47M in revenue, 60.2% of the $203.57M reported across its 3 regions.
Of the Twist Bioscience Corp regions reported in both fiscal 2021 and fiscal 2022, and making up at least 2% of the total, Apac grew the fastest, rising 84.6% from $10.30M to $19.01M.
Every figure is taken from Twist Bioscience Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2017 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.